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Background: Angiosarcomas may develop as primary tumours of unknown cause or as secondary tumours, most commonly
following radiotherapy to the involved field. The different causative agents may be linked to alternate tumorigenesis, which led us
to investigate the genetic profiles of morphologically indistinguishable primary and secondary angiosarcomas.
Methods: Whole-genome (18k) c-DNA-mediated annealing, selection, extension and ligation analysis was used to genetically
profile 26 primary and 29 secondary angiosarcomas. Key findings were thereafter validated using RT–qPCR, immunohisto-
chemistry and validation of the gene signature to an external data set.
Results: In total, 103 genes were significantly deregulated between primary and secondary angiosarcomas. Secondary
angiosarcomas showed upregulation of MYC, KIT and RET and downregulation of CDKN2C. Functional annotation analysis
identified multiple target genes in the receptor protein tyrosine kinase pathway. The results were validated using RT–qPCR and
immunohistochemistry. Further, the gene signature was applied to an external data set and, herein, distinguished primary from
secondary angiosarcomas.
Conclusions: Upregulation of MYC, KIT and RET and downregulation of CDKN2C characterise secondary angiosarcoma, which
implies possibilities for diagnostic application and a mechanistic basis for therapeutic evaluation of RET-kinase-inhibitors in these
highly aggressive tumours.
Angiosarcomas represent a rare and highly aggressive soft tissue
sarcoma subtype with a high risk for local recurrences and distant
metastases (Nascimento et al, 2008; Antonescu et al, 2009;
Neuhaus et al, 2009; Manner et al, 2010; Styring et al, 2010; Guo
et al, 2011; Seinen et al, 2012). Angiosarcomas are broadly divided
into primary and secondary tumours in relation to whether a
predisposing factor, for example, radiotherapy, long-standing
lymphedema or chemical exposure can be identified in which case
the tumours are classified as secondary angiosarcoma (Stewart and
Treves, 1948; Mark et al, 1976; Popper et al, 1978; Body et al, 1987;
Karlsson et al, 1998; Lipshutz et al, 2002; Styring et al, 2010;
Shon et al, 2011). About 40% of secondary angiosarcomas are
estimated to develop following radiotherapy for breast cancer
(Kirova et al, 2005). Even if the absolute risk of secondary
angiosarcoma after radiotherapy for breast cancer is estimated to
be o0.5%, improved breast cancer survival rates imply that an
increasing number of individuals are at risk of this rare
complication. Altered treatment principles for breast cancer are
reflected in a changing presentation of secondary angiosarcomas—
from tumours that present in the upper extremity following many
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years of long-standing lymphedema, that is Stewart-Treves
syndrome, to tumours that present after 5–10 years within the
irradiated field (Stewart and Treves, 1948; Body et al, 1987; Billings
et al, 2004; Brenn and Fletcher, 2005; Styring et al, 2010).
Morphologically, primary and secondary angiosarcomas appear
indistinguishable. Molecular studies have demonstrated upregula-
tion of MYC and KDR in secondary angiosarcomas compared with
primary angiosarcomas and atypical vascular lesions (Antonescu
et al, 2009; Manner et al, 2010; Guo et al, 2011; Fernandez et al,
2012; Mentzel et al, 2012; Kacker et al, 2013). With the aim to
delineate genetic discriminators of primary and secondary
angiosarcomas and to identify key tumorigenic pathways in these
tumours, we applied whole-genome expression profiling to 26
primary and 29 secondary angiosarcomas.
MATERIALS AND METHODS
Sample selection and histopathological evaluation. Adult (418
years) patients with angiosarcoma were eligible for the study.
Primary angiosarcomas were included irrespective of the patient’s
sex and the anatomical tumour location. Secondary angiosarcomas
were defined as sarcomas located in an irradiated field that
developed minimum 3 years after treatment for the primary
tumour and were required to show an angiogenic histology that
differed from that of the primary tumour (Cahan et al, 1948; Arlen
et al, 1971; Cahan, 1998). All secondary angiosarcomas developed
following radiotherapy for primary breast cancer. The cases were
identified using the Swedish Cancer Registry, the Southern Sweden
Pathology Register and the Registry of Histopathology and
Cytopathology in the Netherlands (PALGA) and the patients had
been treated at the Lund Sarcoma Center, Sweden (covering
1.7 million inhabitants) and at the University Medical Center in
Groningen, the Netherlands (covering 1.8 million inhabitants). In
total, 46 primary and 37 secondary angiosarcomas were identified
from which formalin-fixed, paraffin-embedded tissue could be
retrieved from 38 primary and 35 secondary angiosarcomas.
Outcome data has previously been presented for the secondary
angiosarcomas (Styring et al, 2010; Seinen et al, 2012). All cases were
morphologically reviewed by an experienced sarcoma pathologist
(HAD) based on Hematoxylin and Eosin-stained sections and
complementary immunohistochemical stainings for CD31 (Dako,
Glostrup, Denmark; clone JC70A, diluted 1 : 30), CD34 (Dako, clone
QBEnd-10, diluted 1 : 50) and anti-human cytokeratin (Dako, clone
AE1/AE3, diluted 1 : 50).
RNA isolation and gene expression analysis. Adequate tumour
material for RNA extraction was available from 26 primary and
29 secondary angiosarcomas. Clinical characteristics are described
in Table 1. The tumour blocks were median 11 (2–29) and 6 (2–35)
years old in the primary and the secondary angiosarcoma subsets,
respectively. Biological replicates (from different tumour areas in
two primary and five secondary angiosarcomas) were included.
Macro-dissection of non-necrotic tumour areas was performed
followed by RNA extraction of three 10-mm sections using the
High Pure RNA Paraffin Kit (Roche, Castle Hill, Australia)
according to the manufacturer’s instructions. Concentrations of
RNA were determined using a NanoDrop Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA) and samples
yielding sufficient RNA (350 ng) with 260/280 ratios41.8 were
selected. Gene expression analysis was performed at the SCIBLU
Genomics Centre, Lund University, Sweden. The Illumina Bead-
array (HumanWG-6 v4 Expression Beadchip; Illumina, San Diego,
CA) system was used according to the manufacturer’s instructions.
Expression data were uploaded and processed in the Genome-
Studio software (Illumina). Data were normalised using background
correction and the cubic spline method (Workman et al, 2002).
RefSeq features with a detection P-valuep0.01 in at least 80% of the
samples were included, leaving 14 382 features for further analysis.
The data were uploaded into MeV 4.7.4 (Saeed et al, 2003) where
they were log 2-transformed and median-centered across assays.
Unsupervised hierarchical clustering was performed using the
Pearson Correlation and average linkage clustering. All replicates
clustered together, which motivated inclusion of one of the replicate
signatures in the further analysis. Significance analysis for micro-
arrays (SAM) (Tusher et al, 2001) was used to identify differentially
expressed genes in primary and secondary angiosarcomas with a false
discovery rate (FDR) of 0% and a fold change of minimum 2.0.
Biological pathways and gene ontology (GO) terms were identified
using the web-based Database for Annotation, Visualization and
Integrated Discovery 6.7 (DAVID) (Huang da et al, 2009) software
with a FDRp5%. Clinical characteristics are described in Table 1.
The gene expression data can be accessed through GEO accession
number GSE52664.
Validation of gene expression results using reverse transcription
quantitative PCR (RT–qPCR). Representative primary (n¼ 10)
and secondary (n¼ 10) angiosarcomas with stable gene expression
data and sufficient biological material were selected for validation
of the DASL results. Expression levels of MYC (Hs99999003_m1),
RET (Hs01120027_m1) and CDKN2C (Hs00176227_m1) were
determined using RT–qPCR. Briefly, 3 mg of total RNA was
reversely transcribed (Quantitect Reverse Transcription Kit,
Qiagen, Hilden, Germany) and cDNA corresponding to 50
(MYC, UBC, RPS17) or 240 (RET, CDKN2C) ng of total RNA
was used as a template in qPCR (Quantitect Probe PCR Kit,
Qiagen) with predesigned hydrolysis probe assays (Taqman, Life
Technologies, Applied Biosystems, Warrington, UK). The UBC
(Hs00824723_m1) and RPS17 (Hs02386586_g1) genes were used
as endogenous reference. The cDNA pooled from two heman-
gioma tissue specimens served as normaliser. All samples were run
in triplicate. A dilution series to verify reaction efficiency as well as
no template controls were included in each run. Expression ratios
were calculated by the 2DDCT formula. Wilcoxon’s rank sum test
was used to compare expression ratios between primary and
secondary angiosarcomas and the results were visualised using
scatterplots.
Immunohistochemical expression of target proteins. Immuno-
histochemical expression was evaluated in 4-mm sections from
tissue microarray blocks (RET, KIT, CDKN2C) or regular tumour
blocks (KDR). The antibodies used were KIT (A4502, Dilution
1 : 400, Dako), RET (MA1-26379, Dilution 1 : 25, Thermo
Scientific, Waltham, MA, USA), CDKN2C (NB120-3216, Dilution





Number of patients 26 29
Age at diagnosis (median, range) 68 (3–91) 68 (50–90)
Sex (f/m) 16/10 29/0
Location
Head and neck 6 —
Upper extremity 3 2
Thoracical wall 5 27
Lower extremity 4 —
Other locations 8 —
Median years between breast
cancer and angiosarcoma
— 8 (4–20)
Abbreviations: f¼ female; m¼male.
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1 : 25, Novus Biologicals, Cambridge, UK) and KDR (Clone 55B11,
Dilution 1 : 100, Cell Signaling, Danvers, MA, USA). The KIT
staining was defined as positive or negative while the remaining
stainings were graded in three-tier scales (Antonescu et al, 2009).
All stainings were independently scored by two investigators
(ES and MN) with agreement in 495% of the cases. Correlation
between the gene expression analysis and the immunohistochem-
ical result was evaluated using Pearson’s product-moment
correlation test. Comparison between the immunohistochemical
expression patterns in primary and secondary angiosarcomas was
assessed using Wilcoxon’s rank sum test with statistical signifi-
cance set at Po0.05.
External validation. To validate the 103-gene signature identified
in primary vs secondary angiosarcomas, we applied our gene
signature to the E-MEXP-3271 data set consisting of 7 primary and
18 secondary angiosarcomas of which the latter had developed
following radiotherapy for breast cancer (Hadj-Hamou et al, 2012).
A gene expression centroid was constructed by averaging the
expression values of the samples in primary and secondary
angiosarcomas for each gene in order to establish a signature
classifier for nearest centroid classification. A sample from the
external data set was assigned to either of the two subsets based on
the maximum Pearson correlation of its centroid expression to the
angiosarcomas centroid values. Further, we applied the external
transcriptome signature for secondary angiosarcomas (Hadj-
Hamou et al, 2012) to our data using supervised hierarchical
clustering.
RESULTS
Target genes and key pathways. Unsupervised hierarchical
cluster analysis did not separate primary from secondary
angiosarcomas (Figure 1). The SAM analysis, however, identified
103 genes that were significantly deregulated comparing primary
and secondary angiosarcoma (Figure 2 and Supplementary
Table 1). In secondary angiosarcoma, 54 genes, including MYC,
KIT and RET, were upregulated and 49 genes, including CDKN2C,
were downregulated (Table 2 and Supplementary Table 1).
Additional genes with fold changes 42.0, some not previously
described, were included but were not limited to, UNC5A, CTLA4,
ISLR2, ICOS, RAB17, FLT4 and RASGRP3. The DAVID analysis
identified significant upregulation of the receptor protein tyrosine
kinase pathway (EC number 2.7.10.1; FDR 4.4%, Po0.01) based
on overrepresentation of, for example, RET, KIT and FLT4.
In primary angiosarcomas, SAM analysis identified 49 upregu-
lated genes, which included NTSR-1, ANKRD1 and CDKN2C. No
significant deregulated pathway was identified, but seven GO-
terms, including cytokine receptor activity, regulation of cell size,
the cell membrane and cell adhesion were enriched in primary
angiosarcomas compared with secondary angiosarcomas.
RT–qPCR. RT–qPCR confirmed significant (Po0.005) upregula-
tion of MYC and RET and downregulation of CDKN2C in
secondary angiosarcomas compared with primary angiosarcomas
and hemangioma (Figure 3).
Immunohistochemical profiles. Immunohistochemical stainings
focused at key target proteins with differential expression between
primary and secondary angiosarcomas. KDR was highly expressed
in 36 out of 39 secondary angiosarcomas and was thus significantly
over-expressed secondary angiosarcomas (Figure 4). The Pearson’s
product-moment correlation test showed significant correlation
between the immunohistochemical staining and the gene expres-
sion profile for KDR (r¼ 0.6; P¼ 3 10 7). Also KIT expression
showed significant correlation between the immunostaining and
the gene expression profile (r¼ 0.33; P¼ 0.01), but did not reveal
differential immunostaining between primary and secondary
angiosarcomas. For RET and CDKN2C immunostaining and gene
expression, data were not significantly correlated, which suggest
other or more complex mechanisms of action than protein or gene
overexpression.
External validation. The 103-gene signature identified between
primary and secondary angiosarcomas in our series was applied to
the sample set used by Hadj-Hamou et al (2012) (accession
number E-MEXP-3271) . The 103-signature achieved separation of
the 25 tumours of the external data set into primary and secondary
angiosarcoma (Figure 5). The more limited 53-gene signature
suggested by Hadj-Hamou et al (2012) was conversely applied to
our data set. However, only 29 genes were shared and they did not
allow for separate clustering between primary and secondary
angiosarcomas (data not shown).
DISCUSSION
Primary and secondary angiosarcomas in our series show
expression profiles with 103 significantly deregulated genes
(Figure 2 and Supplementary Table 1). Key target genes between
Green: primary
Blue: secondary
Figure 1. Unsupervised hierarchical clustering of the 28 primary
(green) and 34 secondary (blue) angiosarcomas (X-axis). Samples with
similar gene expression profiles cluster together. The full heat map is


















Figure 2. Heat map (SAM analysis) of the 103 genes (Y-axis) expressed
at significantly different levels between 28 primary (green) and 24
secondary (blue) angiosarcomas. Samples with similar gene expression
profiles cluster together on the X-axis. Upregulated expression is
marked with red, and downregulated with green and black reflects no
difference in expression levels.
Genetic profiles in secondary angiosarcoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.359 409
the subsets included MYC, KIT, RET and CDKN2C. Whereas MYC
and KIT have been linked to secondary angiosarcoma, involvement
of RET and CDKN2C has not previously been described in this
tumour type. Deregulation of MYC, RET and CDKN2C was
validated using RT–qPCR and immunohistochemistry. Additional
genes, not previously described in secondary angiosarcomas,
included UNC5A, CTLA4, ISLR2, ICOS, RAB17 and RASGRP3.
FLT4, which has been previously been described (Guo et al, 2011)
was upregulated with a fold change of 2.0 in our series.
Secondary angiosarcomas showed upregulation of RET signal-
ling and consequently downregulation of the down-stream target
CDKN2C (Table 2). Activation of RET linked to mutations in RET
and protein overexpression has been reported at high frequencies
in radiation-associated thyroid cancer (Bounacer et al, 1997;
Collins et al, 2002). Functional studies also support synergistic
effects from RET activation and CDKN2C inactivation (De Falco
et al, 2007; Joshi et al, 2007; van Veelen et al, 2008; Kulkarni and
Franklin, 2011). N-MYC represents a down-stream target of RET
and a key step in CDKN2C downregulation. In multiple endocrine
neoplasia type 2 and in medullary thyroid cancer, N-MYC
induction has been identified as a key tumorigenic step associated
with downregulation of CDKN2C (Kulkarni and Franklin, 2011).
Involvement of MYC, RET and FLT4 has been reported in
secondary angiosarcomas as well as in other radiation-induced
tumours (Antonescu et al, 2009; Manner et al, 2010; Guo et al,
2011; Fernandez et al, 2012; Hadj-Hamou et al, 2012; Mentzel et al,
2012; Kacker et al, 2013). Our findings of MYC, RET and FLT4
upregulation and CDKN2C downregulation thus suggest shared
tumorigenic mechanisms between different types of radiation-
induced tumours.
We found a strong immunohistochemical expression for KDR
(Figure 4) in 36 out of 39 secondary angiosarcomas. The
upregulation at the protein level was significantly correlated to
increased gene expression levels. Our results are consistent with
previous reports of upregulation of vascular-specific receptor
tyrosine kinases, for example, TIE1, KDR and FLT1 in angiosar-
coma (Antonescu et al, 2009). KDR regulates endothelial cell
survival, proliferation, migration and vascular formation during
Table 2. Selected deregulated genes with their respective fold changes
Gene Definition Chromosome Fold change
MYC V-myc myelocytomatosis viral oncogene homologue 8 3.7
RET Ret proto-oncogene (RET-ELE1, MEN2A, MEN2B, RET51) 10 3.0
KIT V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homologue (CD117, C-KIT) 4 2.1
FLT4 Fms-related tyrosine kinase 4 (FLT4) 5 2.0
CDKN2C Cyclin-dependent kinase inhibitor 2C (INK4C, p18) 1 0.5






































Figure 3. Scatterplots demonstrating the RT–qPCR expression ratios (Y-axis) in primary and secondary angiosarcomas (X-axis) in relation to the
pooled reference genes. In secondary angiosarcoma upregulation affects (A) MYC and (B) RET, whereas downregulation is demonstrated for (C)
CDKN2C.
A B C
Figure 4. Immunohistochemical staining for KDR Immunohistochemical staining for KDR in (A) a primary angiosarcoma with low expression,o20%
of the cells positive; (B) secondary angiosarcoma with intermediate expression, X20% but o75%; (C) secondary angiosarcoma with high
expression, immunoreactivity475% of the cells. Grading was performed according to Antonescu et al, (2009). The expression intensities were
determined in the areas with highest staining intensity.
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embryonic development and tumorigenesis (Koch et al, 2011).
Activating mutations in KDR have been demonstrated in 10% of
angiosarcomas and have been linked to tumour localisation in the
breast (Antonescu et al, 2009).
The 103-gene signature achieved reproducible clustering of
primary and secondary angiosarcomas in an external data set
(Figure 5). The ability of our signature to cluster independent
angiosarcomas suggests a stable and reproducible performance of
our results.
Angiosarcomas are aggressive malignant tumours that are
generally resistant to chemotherapy and represent a tumour subset
where novel therapeutic approaches are needed. Identification of
RET signalling as a key feature in secondary angiosarcomas
suggests that treatment with RET-kinase-inhibitors may be
relevant to evaluate in this tumour subset. Although no specific
RET-inhibitor is available, several multi-kinase-inhibitors such as
sorafenib, vandetanib and sunitinib, inhibit the RET kinase and
cause tumour growth arrest in preclinical models (Herbst et al, 2007).
In phase I–II clinical trials, RET inhibitors have shown limited effects
in mixed series of soft tissue sarcomas (Maki et al, 2009). Previous
trials have not selected patients based on primary vs secondary
angiosarcomas or RET status; a response rate of 14% has been
reported in angiosarcomas (Maki et al, 2009). Our data suggest
that further studies of RET inhibitors should consider secondary
angiosarcoma and evaluate clinical benefit in relation to RET status.
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